Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
Tourmaline Bio, Inc. (TRML)
Company Research
Source: GlobeNewswire
– Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 – – Deepak L. Bhatt, MD, MPH, MBA and Dipender Gill, MD, PhD join Cardiovascular Scientific Advisory Board – – Company nominates abdominal aortic aneurysm as second cardiovascular indication for pacibekitug, expanding development for inflammation-driven cardiovascular disease – NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today is hosting its Investor Day, beginning at 10 a.m. ET, during which it will outline progress across its pipeline and provide updates on its strategic priorities. “We continue to be laser-focused on our development efforts for pacibekitug in order to maximize the potential of this program,” said S
Show less
Read more
Impact Snapshot
Event Time:
TRML
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRML alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRML alerts
High impacting Tourmaline Bio, Inc. news events
Weekly update
A roundup of the hottest topics
TRML
News
- Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at Guggenheim.MarketBeat
- Tourmaline Bio, Inc. (NASDAQ: TRML) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock.MarketBeat
- Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.MarketBeat
- Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day [Yahoo! Finance]Yahoo! Finance
- Tourmaline Bio, Inc. (NASDAQ: TRML) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $50.00 price target on the stock.MarketBeat
TRML
Earnings
- 11/7/24 - Beat
TRML
Sec Filings
- 12/10/24 - Form 8-K
- 12/10/24 - Form 8-K
- 11/15/24 - Form EFFECT
- TRML's page on the SEC website